Other parameters did not change significantly from cycles 1 to 4, but cycle 5 observed a decreasing trend (mean ± SD = −57.1 ± 59.6), remaining below baseline except for one parameter, which increased by 34.8 ± 13.7 in cycle 10.
← all excerpts
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
1
—
—